Ask the Expert: Avastin for Recurrent Glioblastoma Multiforme

What is Avastin?

Avastin® (Bevacizumab) is the first and only biologic treatment approved by Health Canada for recurrent glioblastoma multiforme (GBM), which offers an additional treatment option for people with the disease.

How is Avastin administered?

Avastin is given as a single agent at 10 mg/kg intravenously, once every two weeks.

How does Avastin work?

Avastin directly targets the tumour by controlling its growth and extends survival with only a limited impact on quality of life.

Is Avastin approved by Health Canada?

Health Canada approved Avastin in March 2010 as treatment for recurrent GBM.

How do patients access Avastin?

The answer to this question depends on:

  • The province in which the patient lives: In British Columbia, Saskatchewan and Manitoba, there is public access for Avastin in recurrent GBM via provincial drug plans.
  • Whether the patient has private insurance that provides coverage for Avastin.

Beyond the provinces where there is provincial coverage, access to Avastin depends on the type of private insurance coverage each patient may have (often from an employer). Once prescribed Avastin by their oncologist, a patient will contact their insurance carrier to determine coverage.

Please note, however, reimbursement via private insurance coverage is often granted on a case-by-case basis and may not be guaranteed.

There is also a Roche Patient Assistance Program (RPAP) in place to help patients access Avastin.

How do patients connect with the RPAP program?

For reimbursement navigation and coordination, financial assistance and infusion support services, patients should work with their oncologist to enrol in RPAP or call the program directly, toll-free, at 1-888-748-8926, Monday to Friday, 8:00 am to 8:00 pm Eastern Standard Time. Patients can also visit the RPAP website for more information.

Find more information about how to access Avastin

What is the most recent information about Avastin?

New research about the brain tumour treatment Bevacizumab (Avastin®) was released at the recent American Society of Clinical Oncology (ASCO) 2013 Annual Meeting. Results were presented from two recent clinical trials focused on the treatment. Read our summary of the results.

Find more information about advocacy on behalf of a patient or advocacy in support of the brain tumour community in the advocacy section of the website.
Download this information as a Brain Tumour Foundation of Canada Information Sheet (pdf)

Return to Information Sheets here.

This information is provided for information purposes only, and do not represent advice, an endorsement or a recommendation, with respect to any product, service or business, and/or the claims and properties thereof, by Brain Tumour Foundation of Canada. Always consult your health care team if you have questions about your medical care and treatments options.

Share This

Featured Story

"We need all hands on deck" Changing the future of brain tumour research

In Dr. Porter’s lab, Spencer worked on a medulloblastoma project, looking into ways to stop the brain cancer cells from dividing and spreading to other parts of the body. By developing a model to test drug treatments on different cell lines in order to gain a better understanding of how the cells react, Spencer says it could lead to a way to improve the lives of children affected by medulloblastoma – one of the most aggressive pediatric brain cancers.

Learn more

Spotlight

Mya's Story "Just try to relax and be brave"

Bringing hope to children and families in the brain tumour community is important to Mya and Brooke. It’s been a tough couple of years...

Learn more

Five brain tumour survivors are following their dreams thanks to you!

...

Learn more

Upcoming Events

  • 22/Oct/2014: Brain Tumour Awareness Month: Learn more >
  • 22/Oct/2014: St. John's Brain Tumour Support Group: Meets at Room 3018, University Centre - 1 Attic Avenue... Learn more >
  • 22/Oct/2014: Montreal Community Forum/Lancement des activités de la fondation à Montréal: Launching the expansion of programs in Montreal, Quebec.... Learn more >
  • 23/Oct/2014: Sarnia Support Group: Meets at St. Giles Presbyterian Church,770 Lakeshore Road Sarnia, ON... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2014 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001
Imagine Canada Ethical Code